Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Exploring the Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy: A Prospective Study

NCT07167446 is registered in ClinicalTrials.gov with Fox Chase Cancer Center as lead sponsor.

NCT NCT07167446
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07167446 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Exploring the Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy: A Prospective Study
Lead sponsor
Fox Chase Cancer Center
Phase
Phase 1
Overall status
Recruiting
Start date
October 14, 2025
Completion date
September 7, 2028
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer (crc), oxaliplatin induced peripheral neuropathy in cancer patients, peripheral neuropathy due to chemotherapy